Significant or Not? The Health Canada Decision That Holds Up Your Change

Every manufacturer selling a Class III or IV device in Canada eventually faces the same question. A change is coming, to a component, a supplier, a manufacturing process, a label, and someone has to decide whether it can simply be implemented or whether Health Canada has to see it first.

Get that call right and the change moves. Get it wrong in one direction and you have delayed a change that never needed an amendment. Get it wrong in the other and you have marketed a modified device without the amended licence the regulations require.

Health Canada updated its guidance on interpreting "significant change" on 31 March 2026, expanding on the definition set out in the Medical Devices Regulations. At roughly 100 pages with detailed examples, it is the most substantial reference available for making this determination consistently. This post covers what the guidance is for, where its scope reaches further than teams expect, and what has to be documented whichever way the decision goes.

What The Guidance Decides

The purpose is narrow. It helps manufacturers determine whether a proposed change to a Class III or IV medical device licence is significant, which in turn determines whether an amended licence application must be submitted before the change is implemented.

The regulatory hook is section 34 of the Medical Devices Regulations, which describes the changes that require a licence amendment application, including a significant change proposed to a licensed Class III or IV device under subsection 34(a).

The guidance sets out the types of changes captured by the regulatory definition and pairs them with worked examples, so that manufacturers interpret the same regulation the same way. Health Canada is explicit that the examples illustrate rather than exhaust the possibilities. It is not feasible to describe every change a device might undergo, so judgement still applies.

Where The Scope Reaches Further Than Expected

Two points in the scope section are worth reading closely, because both catch teams out.

The first is the breadth of what counts as a modification. A change to a medical device may involve its design, function, safety, manufacturing, packaging, finishing or labelling. Teams that think of "significant change" as a design question alone will miss the manufacturing, packaging, and labelling routes into the same analysis.

The second is the reach into Class II. The guidance should also be consulted for proposed changes to a Class II device that is intended to be used with a separate Class III or IV device. Where the change may affect the safety and effectiveness of the higher-risk device, an amendment application may be required for that higher-risk device before the Class II change is implemented. If your portfolio includes accessories or components used with higher-class devices, the change control analysis has to look across the pairing rather than at the Class II device in isolation.

There are boundaries. The guidance does not apply to devices authorised under Part 1.1 in the context of an urgent public health need, and it does not apply to drug-device combination products subject to the Food and Drugs Regulations, though it does apply to combination products subject to the Medical Devices Regulations.

The Obligation That Applies Either Way

This is the part most often missed.

If the change is significant, the path is clear. You must submit a medical device licence amendment application and obtain the amended licence before you market or sell the modified device in Canada. Not submit and proceed. Obtain and then proceed.

If the change is not significant, you are not finished. Health Canada states that all changes to the device, including labelling changes, must be documented in your quality management system. Beyond that, changes related to information or documents submitted with your original application still have to be reported to Health Canada at annual renewal. Health Canada suggests itemising these in a table with a brief rationale explaining why each change was not considered significant.

That suggestion is worth treating as a working practice. A team that records its non-significant determinations contemporaneously, each with its rationale, arrives at annual renewal with the table already written. A team that does not spends renewal season reconstructing a year of decisions from memory and change orders. ‍

When The Answer is Not Clear

The guidance anticipates that some changes will resist classification. If you cannot determine whether a proposed change is significant after working through all applicable sections, Health Canada directs you to contact the Medical Devices Directorate, providing a complete description of the proposed change and an explanation of why the determination could not be made.

It is also worth remembering what kind of document this is. Health Canada is explicit that guidance documents are administrative rather than legal instruments, so flexibility can be applied. But alternate approaches must be supported by adequate justification and should be discussed in advance with the relevant program area, rather than asserted after the fact.

‍One further consideration: in some cases a proposed change may affect the structure of the current licence and require a new licence application rather than an amendment. That is a separate determination, covered by Health Canada's guidance on determining medical device application type, and it is worth checking before assuming an amendment is the right route.

Making The Determination Defensible

The practical work sits upstream of the decision. A significant change determination is only as good as the change impact assessment behind it, and that assessment depends on knowing what the change actually touches: the design, the risk file, the manufacturing process, the labelling, and any higher-class device the product is used with.

Teams that handle this well have a change control procedure that routes every proposed change through an explicit significance assessment, records the reasoning, and links it to the supporting evidence. Teams that struggle tend to make the call informally and document it later, which works until someone asks why a particular change was not considered significant.

‍This is practical interpretation rather than a stated requirement. Health Canada asks you to document changes in your QMS and to report non-significant ones at renewal. How rigorously you evidence the reasoning behind each determination is your decision, and it is the difference between a renewal that goes smoothly and one that generates questions.

How Gladiolus Can Help

Gladiolus QRS supports manufacturers selling into Canada with the change management work that sits behind a significant change determination, with the emphasis on making the call defensible before it is questioned.

We help teams run design change impact assessments that establish what a proposed change actually affects, including where a Class II change reaches into a Class III or IV device it is used with. We review and develop change control procedures so that significance assessment is a documented step with recorded reasoning rather than an informal judgement. Where a change is significant, we support the medical device licence amendment application and the safety and effectiveness evidence behind it. Where it is not, we help build the QMS documentation and the itemised change table with rationales that Health Canada expects at annual renewal.

We also support the related determinations: whether a change affects licence structure enough to require a new application rather than an amendment, and how the change flows through your risk management file and technical documentation.

If you have a change in progress and are unsure which side of the line it falls on, Gladiolus QRS can review the change, the supporting evidence, and your change control process, and help you plan the right regulatory route. Get in touch to discuss change impact assessment, MDL amendment support, or change control procedure development.